Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

On behalf of the Pfizer team, thank you for joining us ... We had a Phase II readout of ponsegromab, which is another in-house discovered and developed by us. We are encouraged by the potential ...

Mikael Dolsten; Chief Scientific Officer & President, Pfizer Research and Development; Pfizer Inc Andrew Baum; Chief Strategy and Innovation Officer & Executive Vice President; Pfizer Inc Louise ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance (1) for both Revenues and Adjusted (2) diluted EPS. The third-quarter 2024 ...

The potential for ponsegromab to become a blockbuster drug exists, but the uncertainties surrounding the trial timeline and strategic execution contribute to maintaining a Hold rating on Pfizer ...

At Least $4 Billion Anticipated by End of 2024 from Cost Realignment Program(5) Approximately $1.5 Billion Expected by End of 2027 from First Phase of Manufacturing Optimization Program Pfizer Inc ...